Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Summary

The primary objective of this study is to evaluate the long term safety and tolerability of simtuzumab (GS-6624) in participants with idiopathic pulmonary fibrosis (IPF) who had previously participated in Gilead clinical trial AB0024-201.

Timeline

Start

2012-10-18

Primary completion

2016-02-19

Completion

2016-02-19

Outcome

Outcome not reported

Stopped: “The Study was terminated due to lack of efficacy.”

Drugs

Indications